Refractory Chronic Cough Clinical Trial
Official title:
COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
Chronic cough (TC), defined by a duration exceeding 8 weeks, is a particularly frequent symptom with a prevalence observed at 9.6% 1. Chronic cough is the cause of a major handicap for patients with a impact on their quality of life 2. Although CT is common, management is often delicate and complex. In studies, asthma, gastroesophageal reflux disease, posterior flushing, rhino-sinusitis, or taking tussigenic medications are common causes of chronic coughs. However, chronic refractory or unexplained cough, which corresponds to cough for which no cause has been found or the treatments directed against the cause of the cough have not made it possible to resolve the cough, is a real problem in practice. nick3. There is currently no prospective data in France on the characteristics of chronic cough (etiologies, response to treatment) and the percentage of refractory cough. The aim of the study is to constitute a French prospective multicenter hospital cohort of chronic cough patients in order to identify, for the first time in France in a prospective and multicenter manner, the frequency of patients with refractory cough among chronic cough patients.
Visit V1: Visit as part of the treatment After obtaining no objection, the patient will complete cough questionnaires Visit V2: Visit as part of the treatment Visit carried out at 3 months with evaluation of the cough on the criteria of severity and quality of life. An evaluation of the response to treatments initiated at visit V1 will be carried out. Visit V3: Visit as part of the treatment Visit carried out at 6 months either by telephone if response to treatment at 3 months (at the discretion of the investigators) or in the investigative center if no response to treatment at 3 months. An evaluation of the cough on the criteria of severity and quality of life will be performed. Visit V4 to V8: Visit within the framework of research Phone call every 6 months made by a research technician. Patient severity and quality of life questionnaires will be issued in advance and completed at the time of telephone contact. The end of research visit corresponds to the V8 visit. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282591 -
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
|
Phase 2 | |
Completed |
NCT03407014 -
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
|
Phase 2 | |
Completed |
NCT02476890 -
Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)
|
Phase 2 | |
Recruiting |
NCT05599191 -
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
|
Phase 3 | |
Recruiting |
NCT03662269 -
Indomethacin for Refractory Chronic Cough
|
Phase 3 | |
Recruiting |
NCT05962151 -
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
|
Phase 2 | |
Recruiting |
NCT05110144 -
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
|
Phase 2 | |
Enrolling by invitation |
NCT05733533 -
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
|
Phase 2 | |
Completed |
NCT02349425 -
A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
|
Phase 2 | |
Recruiting |
NCT05600777 -
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
|
Phase 3 | |
Completed |
NCT05628740 -
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
|
Phase 1 | |
Not yet recruiting |
NCT06213363 -
A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough
|
Phase 1/Phase 2 | |
Completed |
NCT02412020 -
Treatment of Refractory Chronic Cough With PA101
|
Phase 2 | |
Completed |
NCT04678206 -
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
|
Phase 2 | |
Completed |
NCT02612623 -
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
|
Phase 2 | |
Completed |
NCT02612610 -
A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
|
Phase 2 | |
Completed |
NCT02397460 -
Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)
|
Phase 2 | |
Not yet recruiting |
NCT05265871 -
ATP Level and Cough Sensitivity to ATP in Subjects With Refractory Chronic Cough
|